comprehensive -WSS

comprehensive

author：leisure time 2025-09-30 15:16:49 - browse：8

Sarepta - Cambridge -AP — Kristoffer Tripplaar/Sipa via AP

The Food and Drug Administration granted conditional approval Thursday to the first gene therapy for Duchenne muscular dystrophy. Regulators restricted the treatment to younger patients, with additional data required to broaden its use.

The gene therapy, called Elevydis, is made by Sarepta Therapeutics. The company will charge $3.2 million for the treatment, making it the U.S.’s second most expensive drug, behind a recently approved gene therapy for hemophilia. CEO Doug Ingram said on a conference call the price was below what a recently published company-funded analysis found would be cost-effective.

“The approval of Elevidys is a watershed moment for the treatment of Duchenne. Elevydis is the first and only gene therapy approved for Duchenne, and this approval brings us closer to our goal of bringing forward a treatment that provides the potential to alter the trajectory of this degenerative disease,” Ingram said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Congress must reauthorize a committee to support older Americans

focus

WSS

Gain of function research would be limited under House proposal

Pig kidney works a record two months in donated body

FDA panel endorses Alnylam’s heart drug — after picking it apart

Poor hospice wound care hurts patients and families

Readout LOUD podcast: A CRISPR milestone, biotech mixology

FDA's Woodcock to retire early next year

Wikipedia

comprehensive

focus

In Memoriam: Notable people who died in 2023

FDA approves updated Covid vaccines

In age of alternative facts, a scholarly course on calling out crap

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

Affirmative action in medical school literally saved lives

NYU radiologists take on the challenge of expensive MRI machines

Continuity nursing helped my family in our darkest PICU moments

PBM reforms clear House panel

ChatGPT in medicine: STAT answers readers' burning questions

PEPFAR is under serious threat — and so is global health

hotspot

Regeneron agrees to White House price limits on anti

Astellas still sees hope in its gene therapy after four deaths

Walmart eyes Medicare Advantage provider ChenMed

PBM reforms clear House panel

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

Gain of function research would be limited under House proposal

knowledge

focus

leisure time

leisure time